Patent Litigation in the Pharmaceutical and Biotechnology Industries

Gareth E. Morgan studied Biochemistry at Jesus College, Oxford University, and obtained a degree with first class honours in 1991. He then studied for a D.Phil in molecular biology, focussing on the regulation of the gene for human clotting factor IX. His legal studies were completed at BPP Law School in London and he qualified as a solicitor within the IP Department of Herbert Smith in 2000. He then moved to Taylor Wessing in 2005 and subsequently became a partner in the Patents Group in the London office in 2008. In 2010 he moved to DLA Piper to take up a role within the Intellectual Property and Technology Group, again in the firm's London office, specialising in patent-related matters and medicinal regulatory advice. He qualified as a Solicitor Advocate in 2004 and is an Associate Member of both CIPA (the Chartered Institute of Patent Attorneys) and the UNION (European Union of Intellectual Property Practitioners). He is also a member of the AIPPI.

Choosing your forum; Litigating in the US; Litigating in Europe; Litigating pharma patents; Litigating biotechnology patents; The US ITC regime; Medicinal regulatory considerations; Patent term extension and the SPC regime; A unified patent litigation system for Europe; Conclusions.